Clinical Trials Using Anti-CD22 scFv TCRz:41BB-CAR Lentiviral Vector-transduced Autologous T-lymphocytes
Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-CD22 scFv TCRz:41BB-CAR Lentiviral Vector-transduced Autologous T-lymphocytes. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Genetically Engineered Cells (CART22 T Cells) for the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Pediatric Patients
This phase I trial studies the side effects of CART22 T cells in treating pediatric patients with B-cell acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). This study will take the patient's white blood cells (T cells) and change them to turn against the cancer. These changed cells are called CART22 T cells. The T cells will be changed in a way that will allow the cells to identify and kill the tumor cells. This change tells the T cells to go to the tumor cells and turn "on" and potentially kill the tumor cells. The modification is done by gene transfer and results in a genetic change to the T cells. This allows the changed T cells to recognize tumor cells and normal antibody-producing cells called B cells, but not other normal cells in the body.
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania